Tags

Type your tag names separated by a space and hit enter

Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
Am J Med 2005; 118 Suppl 12A:10-5AJ

Abstract

The incidence of type 2 diabetes mellitus is expected to increase dramatically over the next decade. Patients with type 2 diabetes are at a much greater risk for cardiovascular disease (CVD) than are nondiabetic individuals. Consequently, the treatment of CVD risk factors is a healthcare priority in this patient population. Dyslipidemia is a major cardiovascular (CV) risk factor in patients with type 2 diabetes, and it is characterized by elevated triglyceride levels, low high-density lipoprotein (HDL) cholesterol levels, and a preponderance of small, dense low-density lipoprotein (LDL) particles. Subgroup analyses of clinical trial data suggest that treatment of the entire range of lipid abnormalities may reduce CV risk in this patient population. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are the best therapy for LDL cholesterol reduction. A number of statin trials have shown significant CV risk reduction through LDL cholesterol lowering in subgroups of patients with diabetes. The recently published Collaborative Atorvastatin Diabetes Study (CARDS), a placebo-controlled trial conducted solely in patients with type 2 diabetes, terminated 2 years earlier than its anticipated length owing to the significant reduction in number of CV events observed in patients randomized to receive low-dose atorvastatin versus placebo. These results suggest that low-dose statin therapy with atorvastatin results in significant reduction of CV events in patients with type 2 diabetes without prior CVD or high LDL cholesterol levels. Based on this evidence, patients with type 2 diabetes may be candidates for statin therapy regardless of LDL cholesterol level and in the absence of a previous CV event.

Authors+Show Affiliations

Department of Medicine, Royal Free and University College Medical School, Middlesex Hospital, London, United Kingdom. j.betteridge@ucl.ac.uk

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16356802

Citation

Betteridge, John. "Benefits of Lipid-lowering Therapy in Patients With Type 2 Diabetes Mellitus." The American Journal of Medicine, vol. 118 Suppl 12A, 2005, pp. 10-5.
Betteridge J. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118 Suppl 12A:10-5.
Betteridge, J. (2005). Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. The American Journal of Medicine, 118 Suppl 12A, pp. 10-5.
Betteridge J. Benefits of Lipid-lowering Therapy in Patients With Type 2 Diabetes Mellitus. Am J Med. 2005;118 Suppl 12A:10-5. PubMed PMID: 16356802.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. A1 - Betteridge,John, PY - 2005/12/17/pubmed PY - 2006/1/21/medline PY - 2005/12/17/entrez SP - 10 EP - 5 JF - The American journal of medicine JO - Am. J. Med. VL - 118 Suppl 12A N2 - The incidence of type 2 diabetes mellitus is expected to increase dramatically over the next decade. Patients with type 2 diabetes are at a much greater risk for cardiovascular disease (CVD) than are nondiabetic individuals. Consequently, the treatment of CVD risk factors is a healthcare priority in this patient population. Dyslipidemia is a major cardiovascular (CV) risk factor in patients with type 2 diabetes, and it is characterized by elevated triglyceride levels, low high-density lipoprotein (HDL) cholesterol levels, and a preponderance of small, dense low-density lipoprotein (LDL) particles. Subgroup analyses of clinical trial data suggest that treatment of the entire range of lipid abnormalities may reduce CV risk in this patient population. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are the best therapy for LDL cholesterol reduction. A number of statin trials have shown significant CV risk reduction through LDL cholesterol lowering in subgroups of patients with diabetes. The recently published Collaborative Atorvastatin Diabetes Study (CARDS), a placebo-controlled trial conducted solely in patients with type 2 diabetes, terminated 2 years earlier than its anticipated length owing to the significant reduction in number of CV events observed in patients randomized to receive low-dose atorvastatin versus placebo. These results suggest that low-dose statin therapy with atorvastatin results in significant reduction of CV events in patients with type 2 diabetes without prior CVD or high LDL cholesterol levels. Based on this evidence, patients with type 2 diabetes may be candidates for statin therapy regardless of LDL cholesterol level and in the absence of a previous CV event. SN - 1555-7162 UR - https://www.unboundmedicine.com/medline/citation/16356802/Benefits_of_lipid_lowering_therapy_in_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9343(05)00808-9 DB - PRIME DP - Unbound Medicine ER -